Safety & Drug Interactions

Nattokinase & Warfarin: What the Evidence Shows

Nattokinase is a fibrinolytic enzyme with real cardiovascular activity. For anyone on warfarin, this is the interaction that requires serious consideration before purchase.

The Short Answer

No — taking nattokinase alongside warfarin without medical supervision is not safe. The combination carries a significant and documented risk of haemorrhagic complications. This is not a precautionary overstatement: the interaction is mechanistically well-understood, supported by case evidence, and consistent with the pharmacology of both substances. This page explains why.

What Is Nattokinase?

Nattokinase is a serine protease enzyme derived from the fermentation of soybeans by Bacillus subtilis natto. It has documented fibrinolytic activity — it degrades fibrin, the structural protein in blood clots, and has been shown to elevate fibrinolytic activity in human plasma after oral administration. This is the basis of its popularity as a cardiovascular supplement. For the full evidence review, see our Nattokinase Evidence Review.

How Warfarin Works

Warfarin (Coumadin) is a vitamin K antagonist anticoagulant. It exerts its effect by inhibiting the recycling of vitamin K, which is required for the activation of clotting factors II, VII, IX, and X, and the anticoagulant proteins C and S. By reducing the activity of these factors, warfarin slows the formation of the fibrin clot network.

Warfarin has a narrow therapeutic index — the difference between a dose that is therapeutically effective and one that causes dangerous bleeding is small. For this reason, patients on warfarin have their INR (International Normalised Ratio) regularly monitored. Target INR varies by indication: typically 2.0–3.0 for most conditions (atrial fibrillation, DVT prevention), or 2.5–3.5 for mechanical heart valves. An INR above the target range indicates over-anticoagulation — meaning the blood is slower to clot than desired, and spontaneous or trauma-related bleeding risk is elevated.

The Interaction Mechanism

The combination of nattokinase and warfarin creates a dual threat to haemostasis (the body's ability to stop bleeding):

1. Warfarin reduces clotting factor synthesis. This means the fibrin clot formed when a vessel is damaged is already weaker and thinner than normal.

2. Nattokinase degrades the fibrin that does form. Even when a weak clot forms, nattokinase actively breaks it down more rapidly through direct fibrinolysis.

The combined result is a significant impairment of clot formation and stability — far greater than either agent alone. This creates an elevated risk of:

Case Report and Clinical Evidence

Direct RCT evidence for the nattokinase-warfarin interaction does not exist — it would be unethical to deliberately test a potentially dangerous combination in controlled trial conditions. Evidence comes from pharmacological mechanism analysis and clinical case reports.

Multiple case reports in the published literature describe patients on stable warfarin therapy who developed supratherapeutic INR or haemorrhagic events after initiating nattokinase supplementation. The INR often rose above 4.0 (significantly elevated bleeding risk) without any change in warfarin dose or diet. When nattokinase was discontinued, INR returned toward the therapeutic range. This pattern is consistent with a pharmacodynamic interaction (additive effect on anticoagulation) rather than a pharmacokinetic interaction (change in warfarin metabolism).

A published pharmacological analysis by Fujita et al. demonstrated that nattokinase at doses used in commercial supplements produced meaningful fibrinolytic activity in plasma for 2–8 hours after ingestion. This duration of activity overlaps with warfarin's continuous background anticoagulation, creating a window of significantly enhanced bleeding risk.

InteractionRisk LevelEvidence Type
Nattokinase + WarfarinSERIOUS — Do Not Combine Without GP ReviewMechanism + case reports of haemorrhage and supratherapeutic INR
Nattokinase + Apixaban/RivaroxabanSERIOUS — Same risk, less monitoring availableMechanism (additive fibrinolysis); no INR monitoring for NOACs
Nattokinase + Aspirin (75–300 mg daily)MODERATE — Use with cautionAdditive antiplatelet + fibrinolytic activity
Nattokinase + ClopidogrelMODERATE — GP discussion recommendedAdditive inhibition of clot formation
Nattokinase + SerrapeptaseMODERATE — Stacking riskTwo fibrinolytic enzymes; no safety data for combination

What About NOACs (Novel Oral Anticoagulants)?

Patients on apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban face the same fundamental interaction risk with nattokinase — and in some respects a more concerning one. Unlike warfarin, NOACs do not have routine INR monitoring. A patient on a NOAC who develops a dangerous increase in anticoagulation from adding nattokinase has no early-warning monitoring system to catch it before a bleeding event occurs. The absence of routine monitoring does not mean the interaction is absent — it means it is less detectable.

What If I Still Want to Try Nattokinase?

The desire for additional cardiovascular support beyond anticoagulant medication is understandable. However, the appropriate approach is not to self-supplement with fibrinolytic enzymes alongside prescribed anticoagulants. If you are interested in nattokinase or other supplement-based cardiovascular support, the right pathway is:

  1. Discuss explicitly with your prescribing GP or cardiologist
  2. If a trial is agreed, do not start without a plan for INR monitoring (for warfarin patients)
  3. Start at the lowest available dose
  4. Report any unusual bruising, prolonged bleeding, dark stools, blood in urine, or unusual headache immediately

There is no nattokinase dose that is "safe" to add to warfarin without this conversation. The supplement industry's marketing does not prominently disclose this interaction — and that is a significant safety gap.

Who Should Not Take Nattokinase

Safety & Interactions Summary

Nattokinase is a genuine fibrinolytic supplement — this is precisely why it has cardiovascular interest and precisely why it interacts with anticoagulants. The mechanism is the message. Anyone reading about nattokinase's cardiovascular benefits in supplement literature should ensure they are also reading about the blood-thinning interaction with equal attention.

Bottom Line

Taking nattokinase with warfarin is a meaningful safety risk supported by mechanism, pharmacological data, and clinical case reports. The INR-elevating and haemorrhage-potentiating potential of this combination is real. For patients on warfarin or any anticoagulant, nattokinase is not an over-the-counter purchase decision — it requires an explicit conversation with your GP, and the default answer in the absence of that conversation should be: do not take it.

Questions about supplement safety? Visit The Honey Pot, Clonmel

Shop at The Honey Pot → Ireland Health Shop →
Take a wellness break: spa & retreat hotels in Ireland · healthy getaways abroad · eco-friendly stays — 5% back & carbon offset.